Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00318409 · ClinicalTrials.gov registry record · Phase 2
Acceptability of Pharmacologic Treatment for Methamphetamine Dependence Among MSM
A Phase 2 study, sponsored by San Francisco Department of Public Health.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT00318409: Completed Phase 2 study, sponsored by San Francisco Department of Public Health.
NCT00318409 is a Phase 2 study that has completed, run by San Francisco Department of Public Health. The registered enrollment target is 30 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00318409, a Phase 2 study, has completed, sponsored by San Francisco Department of Public Health.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
Studies demonstrate that methamphetamine (meth) use is associated with high-risk sexual behavior among MSM, putting meth-using MSM at extraordinarily high risk for transmitting or acquiring HIV. No studies have tested the feasibility and acceptability of conducting pharmacologic interventions to reduce meth use and meth-associated sexual risk behavior among MSM. The purpose of this pilot study is to determine the feasibility enrolling and retaining meth-dependent MSM into a pharmacologic study of bupropion vs. placebo and measuring the tolerability of and adherence to medication among these participants.
Interventions
- DRUG Placebo
- DRUG Bupropion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2006-09 |
| Est. Completion | 2007-11 |
| Phase | Phase 2 |
What the finished NCT00318409 record still lists
NCT00318409 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00318409 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00318409 about?
NCT00318409 is a clinical study titled "Acceptability of Pharmacologic Treatment for Methamphetamine Dependence Among MSM". Studies demonstrate that methamphetamine (meth) use is associated with high-risk sexual behavior among MSM, putting meth-using MSM at extraordinarily high risk for transmitting or acquiring HIV. No studies have tested the feasibility and acceptability of conducting pharmacologic interventions to red...
What is the current status of trial NCT00318409?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2006-09. Estimated completion is 2007-11.
What interventions are being tested in trial NCT00318409?
The interventions under investigation include: Placebo (DRUG), Bupropion (DRUG).
Who is sponsoring clinical trial NCT00318409?
This trial is sponsored by San Francisco Department of Public Health, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00318409's enrollment target sits among peer trials
30 1582nd of 2000 higher than 332 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia